The global AI in Pathology market was valued at USD 28.75 Million in 2025. It is poised to grow at a CAGR of 9.12% during the forecast period of 2026-2035, and reach USD 68.81 Million by 2035. The market growth is driven by rising demand for digital pathology, increasing adoption of AI-driven diagnostics, and growing need for accurate and faster disease detection. Advanced technologies such as computational pathology and histopathology AI are enhancing workflow efficiency and improving clinical decision-making outcomes through automated analysis and tissue classification.
Iran: Iran's domestic AI in Pathology sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.
Israel: Israel's technology sector, a globally significant innovation hub for cybersecurity, semiconductors, AI, and various specialized verticals, is experiencing operational disruption as engineering teams are reduced by military reservist call-ups. Several Israeli companies supply components, software, and services to global AI in Pathology market participants. Business development activities have been suspended, and some operational timelines extended. However, Israel's proven resilience through previous conflict periods, and the continued operation of critical R&D programmes, suggests the disruption will be temporary rather than structural.
Other key players in the market are Ibex Medical Analytics Ltd., Aiforia Technologies, Paige AI, Inc., DeePathology Ltd., Proscia Inc., and Qritive.
Q1 2026 Market Updates
Geopolitical Impact of Iran, US, and Israel War on the AI in Pathology Market
United States: The AI in Pathology Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. IDC revised U.S. IT spending growth from 12.4% to 11.4% for 2026, with similar revisions across other markets as corporate CFOs apply caution in an inflationary, uncertain macroeconomic environment. Microsoft Azure and AWS reported investigating latency spikes at Middle Eastern data center nodes following missile strikes on Dubai and Doha infrastructure. Semiconductor and electronics supply chains routed through the Gulf region are experiencing disruption, with some production inputs stranded aboard ships unable to transit the Strait of Hormuz. IDC revised U.S. IT spending growth from 12.4% to 11.4% for 2026, reflecting corporate caution in an inflationary environment. Despite overall caution, AI-driven infrastructure investment continues to provide structural demand support. Despite spending caution, AI infrastructure investment continues to grow, with the current crisis reinforcing the case for advanced technology adoption to offset rising labor and materials costs.Iran: Iran's domestic AI in Pathology sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.
Israel: Israel's technology sector, a globally significant innovation hub for cybersecurity, semiconductors, AI, and various specialized verticals, is experiencing operational disruption as engineering teams are reduced by military reservist call-ups. Several Israeli companies supply components, software, and services to global AI in Pathology market participants. Business development activities have been suspended, and some operational timelines extended. However, Israel's proven resilience through previous conflict periods, and the continued operation of critical R&D programmes, suggests the disruption will be temporary rather than structural.
Key Takeaways
Government
- Relevant technology procurement agencies should assess exposure to Gulf-region cloud and semiconductor supply chains, ensuring critical government IT systems have geographic redundancy and are not dependent on disrupted Middle Eastern infrastructure.
- Policymakers should consider technology investment incentives to offset IDC's revised 11.4% U.S. IT spending growth forecast, preventing conflict-driven corporate caution from permanently deferring productive technology capital investment.
- Cybersecurity agencies should elevate threat assessment for government and critical infrastructure systems, as the Iran conflict has been accompanied by extensive cyber operations targeting energy, financial, and communication infrastructure.
Market
- IDC's downward revision of IT spending growth from 12.4% to 11.4% reflects genuine corporate caution, but the structural AI-driven investment cycle remains intact, with the conflict actually creating additional demand for automation, supply chain visibility, and remote operation technology.
- Microsoft Azure and AWS reports of latency spikes at Middle Eastern data center nodes are accelerating enterprise multi-region architecture adoption and geographic redundancy investments that strengthen Ethernet and cloud infrastructure demand.
- The ai in pathology market benefits from the conflict as a demand catalyst in customer-facing applications, as businesses managing supply chain complexity, customer inquiry volumes, and remote operations require scalable technology platforms at unprecedented scale.
Procurement
- Enterprise technology procurement teams should assess Gulf-region cloud infrastructure exposure and request vendor confirmation that critical SaaS and IaaS services have adequate geographic redundancy outside the conflict zone.
- IT procurement managers should advance planned technology deployments from discretionary to priority status where the platform addresses supply chain visibility, remote operations, or customer communication challenges created by the conflict.
- Technology buyers should review semiconductor and electronics supply chains for Gulf-adjacent manufacturing exposure, building buffer inventory for critical components that may face supply disruption.
Key Market Trends and Insights
- North America dominated the market, capturing over 40% of the total revenue share during the historical period.
- Based on component, the software segment led the market, accounting for approximately 51% share in the historical period.
- Based on end use, pharmaceutical and biotechnology companies held the largest share, contributing around 47% of the market during the historical period.
Market Size and Forecast
- Market Size (2025): USD 28.75 Million
- Projected Market Size (2035): USD 68.81 Million
- CAGR (2026-2035): 9.12%
AI in Pathology Market Overview
AI is transforming pathology by enhancing diagnostic accuracy, reducing variability, and enabling faster analysis of complex tissue samples. It supports automated image analysis, precise tumor detection, and improved biomarker identification, aiding early diagnosis and personalized treatment planning. AI-driven tools streamline workflows, reduce manual workload, and increase efficiency in laboratories. The market reached a value of approximately USD 28.75 Million in 2025.AI in Pathology Market Growth Drivers
Accelerating AI Integration and Market Expansion in Pathology Diagnostics
Growing demand for efficient diagnostic workflows and rising adoption of AI‑powered tools are driving innovation in the AI in pathology market. For instance, in January 2026, AstraZeneca announced its acquisition of Boston‑based Modella AI, a firm specializing in multimodal AI models for oncology and pathology insights. This strategic integration is expected to boost AI deployment in clinical labs, accelerating market growth and adoption during the forecast period.AI in Pathology Market Trends
Key trends shaping the market include AI integration, digital pathology adoption, regulatory support, precision diagnostics, and workflow automation.Regulatory Approvals Driving AI Adoption and Market Development
Rising emphasis on precision medicine and increasing regulatory support for AI solutions are strengthening AI in pathology market opportunities. For instance, in August 2025, the FDA granted Breakthrough Device Designation to ArteraAI Prostate, recognizing its potential to transform pathology workflows. This endorsement is anticipated to encourage adoption of AI diagnostic tools, enhance clinician confidence, and expand the overall AI in pathology market in the coming years.AI in Pathology Market Segmentation
Market Breakup by Component
- Software
- Scanners
Market Breakup by Neural Network
- Generative adversarial networks (GANS)
- Convolutional neural networks (CNNs)
- Recurrent neural networks (RNNs)
- Others
Market Breakup by Application
- Drug Discovery
- Clinical Workflow
- Disease Diagnosis and Prognosis
- Other Applications
Market Breakup by End User
- Pharmaceutical and Biotechnological Companies
- Hospitals and Laboratories
- Research and Academic Institutes
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
AI in Pathology Market Share
Software Dominating the Market Segment by Component
The market is increasingly driven by software-based solutions, reflecting the growing need for advanced analytics and digital platforms. Based on the component, the software segment led the market, accounting for approximately 51% share in the historical period. This dominance is supported by rising adoption of AI-powered image analysis, workflow automation tools, and cloud-based pathology platforms. These solutions enable faster and more accurate diagnosis, through whole slide imaging (WSI) and automated analysis, improving efficiency, and reducing manual errors. Continuous advancements in machine learning algorithms further strengthen the role of software in transforming pathology practices globally and enhancing pathologist workflow.Global AI in Pathology Market Analysis by Region
The market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, each contributing differently to overall growth. North America accounted for the largest revenue share of above 40% in the historical period, driven by strong healthcare infrastructure, early adoption of digital pathology, and significant investments in AI technologies. The presence of leading technology providers and research institutions further supports regional dominance. Meanwhile, Asia Pacific is expected to witness notable growth due to expanding healthcare digitization and increasing demand for advanced diagnostic solutions, including slide scanner technologies and innovations in computational pathology.Leading Players in the AI in Pathology Market
The key features of the market report comprise patent analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Koninklijke Philips N.V.
Headquartered in Amsterdam, Netherlands, and founded in 1891, the company is a global leader in health technology and digital innovation. Its AI in oncology portfolio focuses on advanced imaging, digital pathology, and integrated diagnostics to improve cancer detection and treatment planning. The company offers AI-powered radiology solutions, workflow optimization tools, and cloud-based platforms that support precision oncology.F. Hoffmann-La Roche Ltd
Based in Basel, Switzerland, and established in 1896, this pharmaceutical and diagnostics leader plays a significant role in oncology innovation. Its AI-driven portfolio integrates diagnostics, genomics, and real-world data analytics to advance precision oncology. The company leverages AI in biomarker discovery, companion diagnostics, and clinical trial optimization.Hologic, Inc.
Located in Marlborough, Massachusetts, and founded in 1985, the company specializes in medical technology with a strong focus on women’s health and oncology diagnostics. Its AI in oncology portfolio includes advanced imaging systems, particularly for breast cancer screening, such as AI-enabled mammography and diagnostic solutions. The company emphasizes early detection and improved diagnostic accuracy through AI-driven tools.Indica Labs, Inc.
Headquartered in Albuquerque, New Mexico, and founded in 2011, the company is a leader in digital pathology and image analysis software. Its AI in oncology portfolio includes the HALO® platform, which enables quantitative tissue analysis, biomarker assessment, and pathology workflow optimization. The company’s solutions are widely used in cancer research and clinical trials to improve accuracy and reproducibility.Other key players in the market are Ibex Medical Analytics Ltd., Aiforia Technologies, Paige AI, Inc., DeePathology Ltd., Proscia Inc., and Qritive.
Key Questions Answered in the AI in Pathology Market
- What was the AI in Pathology market value in 2025?
- What is the AI in Pathology market forecast outlook for 2026-2035?
- What major factors aid the demand for AI in Pathology market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major AI in Pathology market trends?
- Which component is expected to dominate the market segment?
- Which neural network is projected to lead the market segment?
- Which application is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players in the AI in Pathology market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
1 Preface
3 Global AI in Pathology Market Overview
4 Vendor Positioning Analysis
5 Global AI in Pathology Market Landscape*
6 Global AI in Pathology Market Dynamics
7 Global AI in Pathology Market Segmentation 219-2035
8 North America AI in Pathology Market 219-2035
9 Europe AI in Pathology Market 219-2035
10 Asia Pacific AI in Pathology Market 219-2035
11 Latin America AI in Pathology Market 219-2035
12 Middle East and Africa AI in Pathology Market 219-2035
13 Patent Analysis
14 Grants Analysis
15 Funding and Investment Analysis
16 Strategic Initiatives
17 Supplier Landscape
18 Global AI in Pathology Market - Distribution Model (Additional Insight)
Companies Mentioned
- Koninklijke Philips N.V.
- F. Hoffmann-La Roche Ltd
- Hologic, Inc.
- Indica Labs, Inc.
